Bristol Myers Squibb Company $BMY Holdings Lessened by RTD Financial Advisors Inc.

RTD Financial Advisors Inc. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 57.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 6,732 shares of the biopharmaceutical company’s stock after selling 9,176 shares during the quarter. RTD Financial Advisors Inc.’s holdings in Bristol Myers Squibb were worth $420,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Castleview Partners LLC boosted its position in shares of Bristol Myers Squibb by 6.4% during the 3rd quarter. Castleview Partners LLC now owns 88,876 shares of the biopharmaceutical company’s stock worth $5,546,000 after acquiring an additional 5,350 shares in the last quarter. Mirador Capital Partners LP lifted its stake in Bristol Myers Squibb by 3.3% during the third quarter. Mirador Capital Partners LP now owns 50,389 shares of the biopharmaceutical company’s stock worth $3,144,000 after purchasing an additional 1,594 shares during the last quarter. Bill Few Associates Inc. boosted its holdings in Bristol Myers Squibb by 3.8% in the third quarter. Bill Few Associates Inc. now owns 12,327 shares of the biopharmaceutical company’s stock valued at $769,000 after purchasing an additional 451 shares in the last quarter. Riversedge Advisors LLC boosted its holdings in Bristol Myers Squibb by 8.4% in the third quarter. Riversedge Advisors LLC now owns 21,212 shares of the biopharmaceutical company’s stock valued at $1,324,000 after purchasing an additional 1,637 shares in the last quarter. Finally, Wedmont Private Capital raised its holdings in Bristol Myers Squibb by 26.1% during the third quarter. Wedmont Private Capital now owns 24,267 shares of the biopharmaceutical company’s stock worth $1,514,000 after purchasing an additional 5,024 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BMY has been the subject of several research analyst reports. Zacks Research upgraded shares of Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 23rd. Jefferies Financial Group cut shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research note on Wednesday, August 5th. Wells Fargo & Company set a $65.00 target price on Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, Truist Financial reissued a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $64.96.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.05% of the stock is currently owned by company insiders.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported that its ZENBEXUS (iberdomide) combination achieved superior progression-free survival versus standard of care in the Phase 3 EXCALIBER-RRMM trial for relapsed or refractory multiple myeloma. The results also showed high minimal residual disease-negative complete response rates and could support an application for accelerated FDA approval, strengthening BMY’s oncology pipeline. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
• Positive Sentiment: J.P. Morgan reportedly assigned BMY a Buy rating, while recent commentary highlights the company’s oncology and hematology portfolio and its history of earnings surprises. These factors may support investor confidence in future growth and earnings. Bristol Myers Squibb Receives a Buy from J.P. Morgan

Bristol Myers Squibb Trading Down 0.7%

NYSE BMY opened at $59.18 on Friday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The firm has a market cap of $120.89 billion, a PE ratio of 13.04, a P/E/G ratio of 0.29 and a beta of 0.19. The firm’s fifty day moving average is $64.15 and its two-hundred day moving average is $60.27. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the prior year, the business earned $1.46 EPS. The firm’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.91 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.